278 related articles for article (PubMed ID: 29454961)
1. First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform.
Cao J; Mi Y; Shi C; Bian Y; Huang C; Ye Z; Liu L; Miao L
Biochem Biophys Res Commun; 2018 Mar; 497(2):485-491. PubMed ID: 29454961
[TBL] [Abstract][Full Text] [Related]
2. Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs.
Liu L; Li X; Huang C; Bian Y; Liu X; Cao J; Qu W; Miao L
Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):527-537. PubMed ID: 32436768
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
[TBL] [Abstract][Full Text] [Related]
5. [DRUG-INDUCED LIVER INJURY AND PYRAZINAMIDE USE].
Horita N; Miyazawa N
Kekkaku; 2015 Mar; 90(3):401-5. PubMed ID: 26477109
[TBL] [Abstract][Full Text] [Related]
6. Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study.
Zhao H; Wang Y; Zhang T; Wang Q; Xie W
Med Sci Monit; 2020 Mar; 26():e920350. PubMed ID: 32145061
[TBL] [Abstract][Full Text] [Related]
7. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
[TBL] [Abstract][Full Text] [Related]
9. Currently Used Low-Dose Pyrazinamide Does Not Increase Liver-Injury in the First Two Months of Tuberculosis Treatment.
Horita N; Miyazawa N; Yoshiyama T; Kojima R; Ishigatsubo Y; Kaneko T
Intern Med; 2015; 54(18):2315-20. PubMed ID: 26370854
[TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
Durand F; Jebrak G; Pessayre D; Fournier M; Bernuau J
Drug Saf; 1996 Dec; 15(6):394-405. PubMed ID: 8968694
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
12. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?
Singh J; Garg PK; Thakur VS; Tandon RK
Indian J Physiol Pharmacol; 1995 Jan; 39(1):43-6. PubMed ID: 7705868
[TBL] [Abstract][Full Text] [Related]
13. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
Tostmann A; Boeree MJ; Aarnoutse RE; de Lange WC; van der Ven AJ; Dekhuijzen R
J Gastroenterol Hepatol; 2008 Feb; 23(2):192-202. PubMed ID: 17995946
[TBL] [Abstract][Full Text] [Related]
14. Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach.
Adhvaryu MR; Reddy N; Vakharia BC
World J Gastroenterol; 2008 Aug; 14(30):4753-62. PubMed ID: 18720535
[TBL] [Abstract][Full Text] [Related]
15. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
16. Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.
Hagiwara E; Suido Y; Asaoka M; Katano T; Okuda R; Sekine A; Kitamura H; Baba T; Komatsu S; Ogura T
J Infect Chemother; 2019 Dec; 25(12):1026-1030. PubMed ID: 31229376
[TBL] [Abstract][Full Text] [Related]
17. Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study.
Ji GY; Wang Y; Wu SQ; Liu QQ; Wu JC; Zhang MM; Sandford AJ; He JQ
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706680
[TBL] [Abstract][Full Text] [Related]
18. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
19. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
[TBL] [Abstract][Full Text] [Related]
20. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
